Meixin Shen1, Soon Wei Daniel Lim2, Eugene S Tan3, Hazel H Oon4, Ee Chee Ren5,6. 1. Singapore Immunology Network (SIgN), A*STAR, 8A Biomedical Grove, #03-06, Immunos Building, Singapore, 138648, Singapore. 2. John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA. 3. National Skin Centre (S) Pte Ltd, 1 Mandalay Rd, Singapore, 308205, Singapore. 4. National Skin Centre (S) Pte Ltd, 1 Mandalay Rd, Singapore, 308205, Singapore. hazeloon@nsc.com.sg. 5. Singapore Immunology Network (SIgN), A*STAR, 8A Biomedical Grove, #03-06, Immunos Building, Singapore, 138648, Singapore. ren_ee_chee@immunol.a-star.edu.sg. 6. Department of Microbiology and Immunology, National University of Singapore, 5 Science Drive 2, MD4, Level 3, Singapore, 117545, Singapore. ren_ee_chee@immunol.a-star.edu.sg.
Abstract
INTRODUCTION: Psoriasis is a systemic, chronic inflammatory disease that not only afflicts the skin but is also associated with cardiovascular disease and metabolic syndrome. The strongest susceptibility loci for the disease is within the human leukocyte antigen (HLA) complex, though specific HLA allelic associations vary between populations. OBJECTIVE: Our objective was to investigate HLA associations with clinical phenotypes of psoriasis and metabolic syndrome in Chinese psoriasis cases. METHODS: We conducted an observational case-control study in Singapore with a cohort of psoriasis cases consecutively recruited from an outpatient specialist dermatological center (n = 120) compared with 130 healthy controls. RESULTS: Significant HLA associations with psoriasis were observed with HLA-A*02:07, B*46:01, C*01:02, and C*06:02. The three-locus haplotype of A*02:07-C*01:02-B*46:01 was also significant (odds ratio [OR] 3.07; p = 9.47 × 10-5). We also observed an association between nail psoriasis and HLA-A*02:07 carriers (OR 4.50; p = 0.002), whereas C*06:02 carriers were less prone to have nail involvement (OR 0.16; p = 0.004). HLA-A*02:07 was also identified as a possible risk allele for hypertension (OR 2.90; p < 0.05), and C*01:02 was a possible risk allele for dyslipidemia (OR 3.36; p < 0.05), both known to be common comorbidities in patients with psoriasis. CONCLUSION: Our results demonstrate the growing importance of discerning population-specific clinical phenotypes and their association with certain HLA alleles in psoriasis.
INTRODUCTION:Psoriasis is a systemic, chronic inflammatory disease that not only afflicts the skin but is also associated with cardiovascular disease and metabolic syndrome. The strongest susceptibility loci for the disease is within the human leukocyte antigen (HLA) complex, though specific HLA allelic associations vary between populations. OBJECTIVE: Our objective was to investigate HLA associations with clinical phenotypes of psoriasis and metabolic syndrome in Chinese psoriasis cases. METHODS: We conducted an observational case-control study in Singapore with a cohort of psoriasis cases consecutively recruited from an outpatient specialist dermatological center (n = 120) compared with 130 healthy controls. RESULTS: Significant HLA associations with psoriasis were observed with HLA-A*02:07, B*46:01, C*01:02, and C*06:02. The three-locus haplotype of A*02:07-C*01:02-B*46:01 was also significant (odds ratio [OR] 3.07; p = 9.47 × 10-5). We also observed an association between nail psoriasis and HLA-A*02:07 carriers (OR 4.50; p = 0.002), whereas C*06:02 carriers were less prone to have nail involvement (OR 0.16; p = 0.004). HLA-A*02:07 was also identified as a possible risk allele for hypertension (OR 2.90; p < 0.05), and C*01:02 was a possible risk allele for dyslipidemia (OR 3.36; p < 0.05), both known to be common comorbidities in patients with psoriasis. CONCLUSION: Our results demonstrate the growing importance of discerning population-specific clinical phenotypes and their association with certain HLA alleles in psoriasis.
Authors: M Guarene; A Pasi; V Bolcato; R Cananzi; A Piccolo; I Sbarsi; C Klersy; R Cacciatore; Valeria Brazzelli Journal: Mol Diagn Ther Date: 2018-08 Impact factor: 4.074
Authors: Dorothea M Sommer; Stefan Jenisch; Michael Suchan; Enno Christophers; Michael Weichenthal Journal: Arch Dermatol Res Date: 2006-09-22 Impact factor: 3.017
Authors: Bree A Foley; Dianne De Santis; Els Van Beelen; Louise J Lathbury; Frank T Christiansen; Campbell S Witt Journal: Blood Date: 2008-04-02 Impact factor: 22.113
Authors: P Gisondi; G Tessari; A Conti; S Piaserico; S Schianchi; A Peserico; A Giannetti; G Girolomoni Journal: Br J Dermatol Date: 2007-06-06 Impact factor: 9.302
Authors: Xianyong Yin; Hui Qi Low; Ling Wang; Yonghong Li; Eva Ellinghaus; Jiali Han; Xavier Estivill; Liangdan Sun; Xianbo Zuo; Changbing Shen; Caihong Zhu; Anping Zhang; Fabio Sanchez; Leonid Padyukov; Joseph J Catanese; Gerald G Krueger; Kristina Callis Duffin; Sören Mucha; Michael Weichenthal; Stephan Weidinger; Wolfgang Lieb; Jia Nee Foo; Yi Li; Karseng Sim; Herty Liany; Ishak Irwan; Yikying Teo; Colin T S Theng; Rashmi Gupta; Anne Bowcock; Philip L De Jager; Abrar A Qureshi; Paul I W de Bakker; Mark Seielstad; Wilson Liao; Mona Ståhle; Andre Franke; Xuejun Zhang; Jianjun Liu Journal: Nat Commun Date: 2015-04-23 Impact factor: 14.919
Authors: Yukinori Okada; Buhm Han; Lam C Tsoi; Philip E Stuart; Eva Ellinghaus; Trilokraj Tejasvi; Vinod Chandran; Fawnda Pellett; Remy Pollock; Anne M Bowcock; Gerald G Krueger; Michael Weichenthal; John J Voorhees; Proton Rahman; Peter K Gregersen; Andre Franke; Rajan P Nair; Gonçalo R Abecasis; Dafna D Gladman; James T Elder; Paul I W de Bakker; Soumya Raychaudhuri Journal: Am J Hum Genet Date: 2014-07-31 Impact factor: 11.025